Immunoglobulin: key market research findings
- Increased use of synthetic/recombinant products
- Promising clinical pipeline
Technavio has released a new market research report on the global immunoglobulin products market, which is expected to grow at a CAGR of around 7% between 2016 and 2020. Immunoglobulin products are used to treat primary antibody deficiency, complex immune deficiency disorders, and life threatening infections.Intravenous immunoglobulin (IVIG) is the largest segment of the global immunoglobulin products market. Increase in the number of bleeding disorders, CIDP, and aging population has intensified the use of IVIG for the treatment of off-label indications such as Guillain-Barre syndrome, specific antibody deficiency and inflammatory myopathies. The Americas lead the global immunoglobulin products market, accounting for 70% of the total market share. Much of this market’s growth comes from the well-developed healthcare system coupled with better economic conditions.
The new industry research report from Technavio discusses in detail the key drivers and trends responsible for the growth of this market and its sub-segments.
“Owing to technological advancements, the production and use of synthetic/recombinant plasma products is increasing. Fractionation products of the plasma include immunoglobulins, which are widely used to treat diseases. These recombinant products are manufactured from genetically engineered cell lines by the expression of equivalent proteins. The risk of viral contamination of plasma products can be eliminated by the use of recombinant/synthetic products. HyQvia, Gammanorm, and Octagam are some recombinant products in the market,” says Barath Palada, Lead Analyst, Pharma, Technavio Research
The growing incidence of autoimmune, infectious diseases, hematological, bone marrow transplants, and PID worldwide has pushed pharmaceutical vendors to provide more efficacious and better-tolerated medications. The clinical pipeline for immunoglobulins is vast, and features candidates in different stages of development. For instance, Cytotect 70, Civacir, and IgM Concentrate by Biotest; Anthrax Immune Globulin Intravenous by Emergent Bio-solutions; and GC5101B by Green Cross are expected to be launched during the forecast period. Besides these, some molecules are in Phase I/II, pre-clinical, and discovery stages. These molecules form a robust pipeline for immunoglobulins during the forecast period.
The leading vendors in the global immunoglobulin products market are Baxalta, CSL, Grifols, Biotest Pharmaceuticals, Kedrion, and Octapharma. The companies which are manufacturing and marketing immunoglobulins that can effectively cure diseases, and provide a high safety and efficacy profile, will have a competitive edge over their peers. Moreover, the emerging players will give stiff competition to the established vendors in the market in the coming years.
A more detailed analysis is available in the Technavio report, Global Immunoglobulin Products Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
